It is hoped that the move will help address some of the questions being asked by the HIV community
News
NICE u-turn backs Stelara for UC
Stelara is the first biologic therapy for UC that targets interleukin (IL)-12 and IL-23 cytokines
Mixed results for Sanofi’s Kevzara COVID-19 trial
Kevzara had “no notable benefit” on clinical outcomes when combining the severe and critical groups versus placebo
EC approves Shionogi’s new antibiotic Fetcroja
Fetcroja is the first treatment to provide coverage against all Gram-negative pathogens considered of critical priority
Novacyt to supply DHSC with COVID-19 tests
Novacyt will supply its COVID-19 test to the DHSC for an initial term of six months
US clears label update for AZ’ Lokelma
The drug’s label now includes a dosing regimen specifically to treat hyperkalaemia in patients with end-stage renal disease on stable hemodialysis
Gov’t upscales mobile coronavirus testing units
At least 96 mobile testing units should be ready to be deployed by the start of May
New partnership to explore cellular aspect of COVID-19 infection
The groups hope to discover cellular receptors or binding proteins of COVID-19
AZ/MSD’s Lynparza shows survival benefit in prostate cancer patients
Results from the PROfound trial showed a statistically significant and clinically meaningful improvement in overall survival
GSK’s dostarlimab shows promise in endometrial cancer
The trial’s primary endpoints were confirmed objective response rate and duration of response
Scancell kicks off COVID-19 vaccine development
The firm’s DNA vaccines target dendritic cells to stimulate high avidity T cells that survey and destroy diseased cells
NICE publishes new COVID-19 guidelines
The Institute’s rapid COVID-19 guidelines are being produced in collaboration with NHS England/Improvement and a cross-specialty clinical group
US approves Sanofi’s meningococcal vaccine
The vaccine is currently under regulatory review in Europe
NICE rejects NHS funding for Portola’s Ondexxya
NICE says there is “no direct evidence” that the drug is better than existing treatment
WHO prematurely publishes remdesivir results
Gilead says the study was underpowered and so statistically meaningful conclusions could not be drawn
